Cytotoxic chemotherapy has not been well investigated in non-clear-cell renal cell carcinoma (RCC), but this phase II study assesses the efficacy of carboplatin and paclitaxel in patients with RCC.

Non-clear-cell RCC accounts for only 25%-30% of kidney cancer and has a mixed histology. Given the rarity of these tumors, large-scale prospective trials "will be difficult, if not impossible to ...